DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Defense Medical Research and Development
  4. Research Highlights/News
  5. 2022 Defense Medical Research and Development Program

Defense Medical Research and Development

NEWS RELEASE

Released: August 31, 2022

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Defense Medical Research and Development Program (DMRDP)
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Development Command (USAMRDC) CDMRP provides DMRDP execution management support for DHP core research program areas, including the Joint Program Committee 2 (JPC-2)/Military Infectious Diseases Research Program and JPC-6/Combat Casualty Care Research Program.

The DMRDP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY22 DMRDP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY22 DMRDP Battlefield Wound Management and Infection Research (BWMIR) Award must address at least one of the following Focus Areas:

  • Understanding appropriate wound prophylaxis/empiric treatment strategies throughout continuum of care, regardless of injury status, through preclinical and clinical studies to inform clinical practice guidelines for:
    • Managing hemorrhagic shock/super-massive transfusion, traumatic limb ischemia (secondary to vascular disruption or tourniquet use), complex soft tissue injury/blast injury, open fracture, and/or frost bite, including evaluation of antimicrobial dosing and tissue penetration studies
    • Expanding the understanding of antibiotic use in tissue injury (e.g., systemic versus topical), especially in the context of hemorrhage/resuscitation, blast, and/or delayed evacuation times
  • Understanding combat traumatic wound physiology and wound progression through preclinical and clinical studies to inform clinical practice guidelines and standard of care efficacy and gaps
  • Optimizing prolonged care management of penetrating torso injury by developing solutions for prevention/management of deep space infections (e.g., bacterial or fungal) and delays in care of penetrating abdominal injury
  • Development of analysis and decision support tools to guide traumatic combat wound care and casualty management to triage, prevent and/or treat infections. Examples include:
    • Technologies to determine the types of wound infections at risk of progression to complications and sepsis
    • Tools to evaluate tissue status before devitalization
    • Guided triage/intervention techniques to be used by front-line providers at early stages of care
Award Mechanism Eligibility Key Mechanism Elements Funding
Battlefield Wound Management and Infection Research (BWMIR) Award Extramural and intramural applicants:
Independent investigators at all academic levels (or equivalent)
  • Submission of a Letter of Intent is required prior to full application submission.
  • Supports research that will increase the understanding of complex wound physiology and control of infection, in order to support future application and maturation of products, technologies, and clinical practice.
  • Proposed research must be relevant to active-duty Service Members and the American public.
  • Supports applied and preclinical research, clinical research, and small-scale clinical trials (e.g., first in human, phase 1/1b). Fundamental basic research, phase 2/3 clinical trials are not supported under this funding opportunity.
  • Proposed research must address at least one of the FY22 DMRDP BWMIR Focus Areas.
  • Different funding levels are available based on the scope of research proposed. It is the responsibility of the applicant to select the funding option that is most appropriate for the proposed research project.
    • Funding Level 1 is intended for preclinical research studies supported by substantial preliminary or published data. Clinical research and clinical trials are not allowed.
    • Funding Level 2 includes clinical research and clinical trials supported by substantial preliminary or published data; may include some preclinical activities.
Funding Level 1:
  • Maximum funding of $1,200,000 for total costs (to include direct and indirect costs).
  • Maximum period of performance is 3 years.
Funding Level 2:
  • Maximum funding of $2,200,000 for total costs (to include direct and indirect costs).
  • Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under �Email Subscriptions� on the eBRAP homepage. For more information about the DMRDP or other CDMRP-administered programs, please visit the CDMRP website.

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-ncdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Thursday, December 5, 2024